Select a medication above to begin.
Kimmtrak (tebentafusp-tebn)
tebentafusp
Black Box Warnings .
Cytokine Release Syndrome
serious or life-threatening cases occurred; manifestations may include fever, hypotension, hypoxia, chills, nausea, vomiting, rash, elevated transaminases, fatigue, and headache; ensure providers have immediate access to meds, resuscitative equipment to manage CRS; ensure patients are euvolemic prior to tx start; monitor patients for at least 16h following first 3 infusions, then as clinically indicated
Adult Dosing .
Dosage forms: INJ
Special Note
- [drug name clarification]
- Info: nonproprietary name = tebentafusp-tebn
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing including toxicity-related dose adjustments
HLA-A*02:01-positive uveal melanoma, unresectable or metastatic
- [20 mcg IV x1 on day 1, then 30 mcg IV x1 on day 8, then 68 mcg IV qwk starting day 15 until disease progression]
renal dosing
- [see below]
- CrCl >30: no adjustment; CrCl <30: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin 1.1-1.5x ULN or AST >ULN: no adjustment; bilirubin >1.5x ULN: not defined
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.